Drugs Made In America Acquisition II Corp. Rights (DMIIR)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
DMIIR Chart
Drugs Made In America Acquisition II Corp. Rights Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| SK Steven Katznelson Radcliffe Capital Management LP | 575,000 | $80,500 | $46,575 | -$33,925 | -42.14% |
| BO Brian Oliveira Clear Street Group Inc. | 142,971 | $13,073.22 | $11,580.65 | -$1,492.57 | -11.42% |
| MCS Mercuria Capital Strategies LLC Mercuria Capital Strategies LLC | 750,000 | $60,000 | $62,625 | $2,625 | 4.37% |
| AAS ABC Arbitrage SA ABC Arbitrage SA | 40,000 | $5,600 | $3,340 | -$2,260 | -40.36% |
Drugs Made In America Acquisition II Corp. Rights (DMIIR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Drugs Made In America Acquisition II Corp. Rights ever had a stock split?
Drugs Made In America Acquisition II Corp. Rights Profile
| Capital Markets Industry | Financials Sector | Roger Bendelac CEO | NASDAQ (NMS) Exchange | G2851K112 CUSIP |
| US Country | 2 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Drugs Made In America Acquisition II Corp. is a newly established entity incorporated in 2024. Based in Fort Lauderdale, Florida, the company currently lacks significant operations. Its primary objective is to execute strategic business combinations, including mergers, asset acquisitions, share exchanges, recapitalizations, and reorganizations. The intent behind such activities is to partner with or acquire one or more businesses, ultimately facilitating expansion and growth within specific sectors. This approach is particularly relevant in the pharmaceutical and healthcare industries, which align with the company's name and the potential market it aims to navigate.
Products and Services
- Business Combinations
The company plans to engage in various forms of business combinations, enhancing its portfolio and market presence through strategic alliances and partnerships. This approach allows the firm to leverage the expertise of existing businesses in the pharmaceutical industry.
- Mergers and Acquisitions
Drugs Made In America Acquisition II Corp. aims to identify potential merger or acquisition targets that align with its strategic goals. By consolidating resources and capabilities, the company seeks to create synergies that can drive growth and innovation.
- Reorganizations
Reorganizing existing companies may be part of the company's strategy to improve operational efficiency and align business objectives. Such reorganizations can involve restructuring the management or operational frameworks of acquired entities to enhance performance.
- Asset Acquisition
The company intends to explore opportunities for acquiring assets from distressed or strategically aligned businesses. This could comprise tangible assets, intellectual property, or proprietary technologies that would benefit its future endeavors.
- Recapitalization
Through recapitalization, the company may restructure its financial assets and liabilities, optimizing its capital structure to support growth and operational sustainability. This process could involve raising funds to enhance business capabilities further.
